David is passionate about developing new medicines for patients that improve their quality of life and extend survival. He has served multiple biotechnology companies as an executive, investor, board director, and co-founder. These companies have discovered innovative medicines (including FDA approved drugs) to treat patients with various life threatening and disabling diseases.

As a co-founder and Director of Potentia Pharmaceuticals, Inc. (acquired by Apellis), David helped advance the development of pegcetacoplan, a cyclic peptide that inhibits complement (part of the body's immune system), which is now FDA approved to treat geographic atrophy secondary to age-related macular degeneration (a leading cause of blindness) as well as to treat paroxysmal nocturnal hemoglobinuria.

As an investor on OrbiMed's venture capital team, David helped fund the development of several FDA approved drugs including Amarin’s VASCEPA® for hypertriglyceridemia, Intercept’s OCALIVA® for primary biliary cholangitis, and Arteaus/ Eli Lilly’s EMGALITY® for the treatment of episodic cluster headaches and preventive treatment of migraines.

As COO of Inspirna, Inc., David works with a team of talented scientists, clinicians and business executives and leads operational development of the company’s first-in-class oncology drug candidates through the convergence of strategy, clinical/ nonclinical, licensing, financing, and business/ corporate development efforts. The company's lead program, ompenaclid (RGX-202), is in Phase 2 clinical development to treat RAS mutant metastatic colorectal cancer and acts on a novel creatine transport channel.